A Randomized, Placebo-Controlled Study of the Efficacy and Safety of Fixed-Dose Brexpiprazole 2 mg/d as Adjunctive Treatment of Adults With Major Depressive Disorder.

Hobart M , Skuban A , Zhang P , Augustine C , Brewer C , Hefting N , Sanchez R , McQuade RD
The Journal of clinical psychiatry
To assess the efficacy, safety, and tolerability of brexpiprazole as adjunct to antidepressant treatment (ADT) in adults with major depressive disorder (MDD) and inadequate response to ADTs.

Copyright(C) 2006 BIOIMPACT Co., Ltd. All Rights Reserved